Scynexis completes Phase 1 IV study of antifungal SCY-247
Tweet Send to a Friend
Scynexis (NASDAQ: SCYX) announced topline results from its Phase 1 single and multiple ascending dose trial of the intravenous formulation ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE




